IB 
Union Calendar No. 615 
114TH CONGRESS 
2D SESSION 
H. R. 3537 
[Report No. 114–787, Part I] 
To amend the Controlled Substances Act to clarify how controlled substance 
analogues are to be regulated, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 17, 2015 
Mr. DENT (for himself, Mr. HIMES, Mr. MEEHAN, Mr. DOLD, Mr. TIBERI, 
Mr. COSTELLO of Pennsylvania, Mr. HANNA, Mr. THOMPSON of Pennsyl-
vania, Mr. ROGERS of Kentucky, Mr. MURPHY of Pennsylvania, Mr. 
BARLETTA, Ms. NORTON, Mr. LANCE, Mrs. COMSTOCK, Mr. KATKO, Ms. 
ROS-LEHTINEN, and Mr. JOLLY) introduced the following bill; which was 
referred to the Committee on Energy and Commerce, and in addition to 
the Committee on the Judiciary, for a period to be subsequently deter-
mined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
SEPTEMBER 26, 2016 
Additional sponsors: Mr. RODNEY DAVIS of Illinois, Mr. CUELLAR, Mr. GUTH-
RIE, Mr. THORNBERRY, Mr. BISHOP of Michigan, Mr. KING of New 
York, Mr. ALLEN, Mr. PIERLUISI, Ms. KAPTUR, Mr. PETERS, and Ms. 
VELA´ZQUEZ 
SEPTEMBER 26, 2016 
Reported from the Committee on Energy and Commerce with amendments 
[Strike out all after the enacting clause and insert the part printed in italic] 
SEPTEMBER 26, 2016 
The Committee on the Judiciary discharged; committed to the Committee of 
the Whole House on the State of the Union and ordered to be printed 
[For text of introduced bill, see copy of bill as introduced on September 17, 2015] 
VerDate Sep 11 2014 
22:07 Sep 26, 2016
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\H3537.RH
H3537
srobinson on DSK5SPTVN1PROD with BILLS
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Dangerous Synthetic 
Drug Control Act of 2016’’. 
SEC. 2. TREATMENT OF CERTAIN DESIGNER DRUGS AS 
SCHEDULE I CONTROLLED SUBSTANCES. 
(a) CANNABIMIMETIC AGENTS.—Schedule I, as set 
forth in section 202(c) of the Controlled Substances Act (21 
U.S.C. 812(c)), is amended in subsection (d)(2)(B)— 
(1) in clause (xiv) by striking ‘‘and’’ at the end; 
(2) in clause (xv) by striking the period and in-
serting a semicolon; and 
(3) by adding at the end the following: 
‘‘(xvi) 
2-(2-methylphenyl)-1-(1-pentyl-1H- 
indol-3-yl)ethanone (JWH–251); 
‘‘(xvii) 
(1-butyl-1H-indol-3-yl)(4- 
methylnaphthalen-1-yl)methanone 
(4′-methyl 
JWH–073); 
‘‘(xviii) 
2-(3-methoxyphenyl)-1-(1-pentyl- 
1H-indol-3-yl)ethanone (JWH–302); 
‘‘(xix) 
N-(adamantan-1-yl)-1-(5- 
fluoropentyl)-1H-indole-3-carboxamide 
(5F– 
APICA); 
VerDate Sep 11 2014 
22:07 Sep 26, 2016
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6203
E:\BILLS\H3537.RH
H3537
srobinson on DSK5SPTVN1PROD with BILLS
‘‘(xx) quinolin-8-yl 1-(5-fluoropentyl)-1H- 
indole-3-carboxylate (5F–PB–22); 
‘‘(xxi) 
N-(1-amino-3-methyl-1-oxobutan-2- 
yl)-1-pentyl-1H-indazole-3-carboxamide 
(AB– 
PINACA); 
‘‘(xxii) 
N-(naphthalen-1-yl)-1-pentyl-1H- 
indole-3-carboxamide (MN–24); 
‘‘(xxiii) 
(1-(5-fluoropentyl)-1H-indazol-3- 
yl)(naphthalen-1-yl)methanone (THJ–2201); 
‘‘(xxiv) 
N-(1-amino-3,3-dimethyl-1- 
oxobutan-2-yl)-1-pentyl-1H-indazole-3- 
carboxamide (ADBICA); 
‘‘(xxv) methyl 2-(1-(5-fluoropentyl)-1H-in-
dazole-3-carboxamido)-3-methylbutanoate 
(5F– 
AMB); and 
‘‘(xxvi) methyl 2-(1-(cyclohexylmethyl)-1H- 
indazole-3-carboxamido)-3-methylbutanoate 
(MA–CHMINACA).’’. 
(b) SYNTHETIC OPIOIDS.—Schedule I, as set forth in 
section 202(c) of the Controlled Substances Act (21 U.S.C. 
812(c)), is amended in subsection (a) by adding at the end 
the following: 
‘‘(43) Butyryl fentanyl. 
‘‘(44) beta-Hydroxythiofentanyl. 
‘‘(45) Acetyl fentanyl.’’. 
VerDate Sep 11 2014 
22:07 Sep 26, 2016
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6203
E:\BILLS\H3537.RH
H3537
srobinson on DSK5SPTVN1PROD with BILLS
(c) OTHER DRUGS.—Schedule I, as set forth in section 
202(c) of the Controlled Substances Act (21 U.S.C. 812(c)), 
is amended in subsection (c) by adding at the end the fol-
lowing: 
‘‘(29) 
1-(naphthalen-1-yl)-2-(pyrrolidin-1- 
yl)pentan-1-one (α-naphyrone). 
‘‘(30) 
1-(2,3-dihydrobenzofuran-5-yl)propan-2- 
amine (5–APDB). 
‘‘(31) 
1-(2,3-dihydrobenzofuran-6-yl)propan-2- 
amine (6–APDB). 
‘‘(32) 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6- 
amine (MDAI). 
‘‘(33) 5-iodo-2,3-dihydro-1H-inden-2-amine (5– 
IAI). 
‘‘(34) 
1-(4-bromofuro[2,3-f]benzofuran-8- 
yl)propan-2-amine (bromo-dragonfly). 
‘‘(35) 1-(4-chloro-2,5-dimethoxyphenyl)propan-2- 
amine (DOC). 
‘‘(36) 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2- 
amine (MEM).’’. 
Amend the title so as to read: ‘‘A bill to amend the 
Controlled Substances Act to add certain synthetic sub-
stances to schedule I, and for other purposes.’’. 
VerDate Sep 11 2014 
22:07 Sep 26, 2016
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.RH
H3537
srobinson on DSK5SPTVN1PROD with BILLS
Union Calendar No. 615 
114TH CONGRESS 
2D SESSION 
H. R. 3537 
[Report No. 114–787, Part I] 
A BILL 
To amend the Controlled Substances Act to clarify 
how controlled substance analogues are to be reg-
ulated, and for other purposes. 
SEPTEMBER 26, 2016 
Reported from the Committee on Energy and Commerce 
with amendments 
SEPTEMBER 26, 2016 
The Committee on the Judiciary discharged; committed 
to the Committee of the Whole House on the State of 
the Union and ordered to be printed 
VerDate Sep 11 2014 
22:07 Sep 26, 2016
Jkt 059200
PO 00000
Frm 00006
Fmt 6651
Sfmt 6651
E:\BILLS\H3537.RH
H3537
srobinson on DSK5SPTVN1PROD with BILLS